Condition: Nasopharyngeal Carcinoma · Sponsor: Chongqing University Cancer Hospital
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer. Stereotactic body radiotherapy is a potential immunostimulatory therapy that may amplify antitumor response when combined with camrelizumab.
This description comes directly from the study's public registry record.
Jiangdong Sui, Ph.D, M.D. · 13594190011 · jiangdong.sui@cqu.edu.cn
Ying Wang, Ph.D, M.D. · 13996412826 · yingwang197011@163.com
Always discuss trial participation with your own doctor first.
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Chongqing University Three Gorges Hospital | Wanzhou, Chongqing Municipality, China | Recruiting |
| The Affiliated Hospital of Southwest Medical University | Luzhou, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04830267